Synthesis and antiproliferative activity of (2R,3R)-disubstituted tetrahydropyrans

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 6135-6138

  Carrillo, Romen ^a   León, Leticia G ^a,b   Martín, Tomás ^a,c   Martín, Víctor S ^a   Padrón, José M ^a,b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b Madrid Spain   (Spain)

^c INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

Author keywords

Anticancer drugs; Cyclic ethers; Marine products; Solid tumors; Structure activity relationship

Indexed keywords

TETRAHYDROPYRAN DERIVATIVE;

ARTICLE; CELL LINE; COLON CANCER; CONTROLLED STUDY; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; SOLID TUMOR; SUBSTITUTION REACTION;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYDROGEN; HYDROPHOBICITY; MOLECULAR STRUCTURE; PYRANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750531635     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.094     Document Type: Article

References (19)

1. Mayer A.M.S., and Gustafson K.R. Eur. J. Cancer 40 (2004) 2676 and references therein
2. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Martín V.S. Chem. Med. Chem. 1 (2006) 323
3. Miranda P.O., León L.G., Padrón J.I., Martín V.S., and Padrón J.M. Bioorg. Med. Chem. Lett. 16 (2006) 3135
4. Crisóstomo F.R.P., Padrón J.M., Martín T., Villar J., and Martín V.S. Eur. J. Org. Chem. (2006) 1910
5. Padrón J.M., Donadel O.J., León L.G., Martín T., and Martín V.S. Lett. Drug Des. Discov. 3 (2006) 29
6. Donadel O.J., Martín T., Martín V.S., Villar J., and Padrón J.M. Bioorg. Med. Chem. Lett. 15 (2005) 3536
7. Snatzke G., Raza Z., Habus I., and Sunjic V. Carbohydr. Res. 182 (1988) 179
8. Tri-O-acetyl-d-galactal was purchased from Aldrich Chemical Company (Milwaukee, WI).
9. Carrillo R., Martín V.S., and Martín T. Tetrahedron Lett. 45 (2004) 5215
10. Carrillo R., Martín V.S., López M., and Martín T. Tetrahedron 61 (2005) 8177
11. Ando K. Tetrahedron Lett. 36 (1995) 4105
12. Inanaga J., Hirata K., Saeki H., Katsuki T., and Yamaguchi M. Bull. Chem. Soc. Jpn. 52 (1979) 1989
13. Garcia D.M., Yamada H., Hatakeyama S., and Nishizawa M. Tetrahedron Lett. 35 (1994) 3325
14. 50) represent the drug concentration at which PG is +50, 0, and -50, respectively. Skehan P., Storeng P., Scudeiro D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
15. Cells were inoculated at densities of 7000 (A2780), 6000 (SW1573), and 12,000 (WiDr) cells per well, based on their doubling times. Pure compounds were initially dissolved in DMSO at 400 times the desired final maximum test concentration, that is 100 μM. Control cells were exposed to an equivalent concentration of DMSO. Each agent was tested in duplicate at five different tenfold dilutions. Drug incubation times were 48 h, after which cells were precipitated with 25 μL ice-cold 50% (w/v) trichloroacetic acid and fixed for 60 min at 4 °C. Then the SRB assay was performed. The optical density (OD) of each well was measured at 492 nm using Bio-Tek's PowerWave XS 96-well plate reader. The percentage growth was calculated at each of the drug concentration levels based on the difference in OD at the start and end of drug exposure. Values were corrected for background OD from wells only containing medium.
16. ® appeared the most accurate predictor of Clog P values. Machatha S.G., and Yalkowsky S.H. Int. J. Pharm. 294 (2005) 185
17. ® accessible via Internet (www.daylight.com/daycgi/clogp) working with the Hansch-Leo's 'fragment constant' method.
18. Pizao P.E., Peters G.J., van Ark-Otte J., Smets L.A., Smitskamp-Wilms E., Winograd B., Pinedo H.M., and Giaccone G. Eur. J. Cancer A (1993) 1566
19. Crisóstomo F.R.P., Carrillo R., León L.G., Martín T., Padrón J.M., and Martín V.S. J. Org. Chem. 71 (2006) 2339